These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Uric acid and the development of hypertension. Hwu CM; Lin KH Med Sci Monit; 2010 Oct; 16(10):RA224-30. PubMed ID: 20885365 [TBL] [Abstract][Full Text] [Related]
23. Cochrane Corner: evaluation of the Cochrane systematic review "antiplatelet agents for chronic kidney disease". Caldeira D; Vaz-Carneiro A; Costa J Rev Port Cardiol; 2013 Nov; 32(11):917-8. PubMed ID: 24268867 [No Abstract] [Full Text] [Related]
25. Uric acid in hypertension and renal disease: the chicken or the egg? Kanbay M; Solak Y; Dogan E; Lanaspa MA; Covic A Blood Purif; 2010; 30(4):288-95. PubMed ID: 21088389 [TBL] [Abstract][Full Text] [Related]
26. [Calcium antagonists: current and future applications based on new evidence. The mechanisms on lowering serum uric acid level by calcium channel blockers]. Mizuta E; Hamada T; Igawa O; Shigemasa C; Hisatome I Clin Calcium; 2010 Jan; 20(1):45-50. PubMed ID: 20048433 [TBL] [Abstract][Full Text] [Related]
27. [Extrarenal clearance of the organism from nitrous residues in urological diseases with chronic renal insufficiency]. Rodoman VE; Maksimov VI Urologiia; 1999; (6):51-4. PubMed ID: 16859010 [No Abstract] [Full Text] [Related]
28. Role of oxidative stress on chronic kidney disease progression. Putri AY; Thaha M Acta Med Indones; 2014 Jul; 46(3):244-52. PubMed ID: 25348188 [TBL] [Abstract][Full Text] [Related]
29. [Dyslipidemia as a therapeutic target for prevention of cardiovascular events and end-stage renal disease]. Watanabe T Nihon Rinsho; 2008 Sep; 66(9):1761-9. PubMed ID: 18788407 [TBL] [Abstract][Full Text] [Related]
31. Activation of ATP-sensitive potassium channels protects vascular endothelial cells from hypertension and renal injury induced by hyperuricemia. Long CL; Qin XC; Pan ZY; Chen K; Zhang YF; Cui WY; Liu GS; Wang H J Hypertens; 2008 Dec; 26(12):2326-38. PubMed ID: 19008712 [TBL] [Abstract][Full Text] [Related]
32. Relationship of uric acid with progression of kidney disease. Chonchol M; Shlipak MG; Katz R; Sarnak MJ; Newman AB; Siscovick DS; Kestenbaum B; Carney JK; Fried LF Am J Kidney Dis; 2007 Aug; 50(2):239-47. PubMed ID: 17660025 [TBL] [Abstract][Full Text] [Related]
33. Serum uric acid and its relationship with metabolic syndrome and cardiovascular risk profile in patients with hypertension: insights from the I-DEMAND study. Viazzi F; Garneri D; Leoncini G; Gonnella A; Muiesan ML; Ambrosioni E; Costa FV; Leonetti G; Pessina AC; Trimarco B; Volpe M; Agabiti Rosei E; Deferrari G; Pontremoli R Nutr Metab Cardiovasc Dis; 2014 Aug; 24(8):921-7. PubMed ID: 24675005 [TBL] [Abstract][Full Text] [Related]
34. [Anemia as a risk factor for CKD and CVD]. Tsuruya K; Hirakata H Nihon Rinsho; 2008 Sep; 66(9):1786-93. PubMed ID: 18788410 [TBL] [Abstract][Full Text] [Related]
35. FGF-23: the rise of a novel cardiovascular risk marker in CKD. Heine GH; Seiler S; Fliser D Nephrol Dial Transplant; 2012 Aug; 27(8):3072-81. PubMed ID: 22851630 [TBL] [Abstract][Full Text] [Related]
36. Clinical evidence for the influence of uric acid on hypertension, cardiovascular disease, and kidney disease: a statistical modeling perspective. Short RA; Tuttle KR Semin Nephrol; 2005 Jan; 25(1):25-31. PubMed ID: 15660331 [TBL] [Abstract][Full Text] [Related]